Official Malaysian Government Website
Content category
73 records
To receive the latest issues of Direct Healthcare Professional Communications (DHPCs), join the NPRA Safety Information Mailing List by completing the subscription form.
DISCLAIMER: This publication is intended for healthcare professionals. The information provided aims to update on medication safety issues and should not substitute clinical judgement. While…
DISCLAIMER: This publication is intended for healthcare professionals. The information provided aims to update on medication safety issues and should not substitute clinical judgement. While…
DISCLAIMER: This publication is intended for healthcare professionals. The information provided aims to update on medication safety issues and should not substitute clinical judgment. While…
DISCLAIMER: This publication is aimed at health professionals. The information is meant to provide updates on medication safety issues, and not as a substitute for clinical judgement. While…
DISCLAIMER: This publication is aimed at health professionals. The information is meant to provide updates on medication safety issues, and not as a substitute for clinical judgement. While…
Product Overview Terlipressin (Glypressin®) is a vasopressin analogue indicated for the treatment of type 1 hepatorenal syndrome (HRS), characterised by spontaneous acute renal insufficiency in…
Product Overview Brolucizumab (Pagenax®) is a humanised monoclonal antibody indicated for the treatment of neovascular (wet) age-related macular degeneration (AMD) in adults. At present, there is one…
Product Overview Alectinib (Alecensa®) as monotherapy is indicated for the first-line treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer…
Description Cladribine is indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include relapsing-remitting disease and active secondary progressive disease in adults. Due to…
In Malaysia, Tecentriq® (atezolizumab) is approved for the treatment of non-small cell lung cancer, small cell lung cancer and triple-negative breast cancer. Based on a cumulative analysis on the…
Description Lemtrada® (alemtuzumab) is a disease modifying drug that is indicated in adults with highly active relapsing remitting multiple sclerosis (RRMS). New safety information has been…
Description In Malaysia, fingolimod is indicated for the treatment of relapsing forms of multiple sclerosis (MS) in adult patients and in paediatric patients of 10 years old and above to reduce the…
Description: In Malaysia, Plaquenil® is approved for the treatment of rheumatoid arthritis, juvenile chronic arthritis, discoid and systemic lupus erythematosus, and dermatological conditions caused…
Description: Kyprolis® (carfilzomib) is indicated in combination with dexamethasone or lenalidomide plus dexamethasone for the treatment of patients with relapsed or refractory multiple myeloma who…
Description Esbriet® (pirfenidone) is an anti-fibrotic and anti-inflammatory agent indicated for the treatment of Idiopathic Pulmonary Fibrosis (IPF). Elevations of liver enzymes are a known risk of…
Description: Febuxostat is a non-purine selective inhibitor of xanthine oxidase that reduces the formation of uric acid. It is indicated for the treatment of chronic hyperuricaemia in conditions…
Overview Smecta® (dioctahedral smectite) is an edible natural clay used for the symptomatic treatment of diarrhoea. Background of Safety Issue NPRA has received information from the French National…
Description: LEMTRADA® (alemtuzumab) is indicated for the management of adult patients with relapsing remitting multiple sclerosis (RRMS), with active disease defined by clinical and imaging…
Description: Actemra® (tocilizumab) is a biological product indicated for rheumatoid arthritis in adults, polyarticular systemic juvenile idiopathic arthritis (pJIA) and systemic juvenile idiopathic…
Description: Zopiclone is a hypnotic agent, indicated for the treatment of insomnia. It is recommended to be used for the shortest duration possible, and not exceeding 4 weeks. The risk of developing…
Description TECENTRIQ® (atezolizumab) has been associated with the risk of immune-related myositis. In a comprehensive analysis that was performed across the TECENTRIQ® programme, cases of…
Description An increased risk of serious psychiatric events such as depression, suicidal ideation or behavior, including suicides, or self-injury, has been observed in patients with systemic lupus…
Description Children exposed in utero to valproate are at risk of serious developmental disorders (in up to 30-40% of cases) and congenital malformations (in approximately 10% of cases). Previously…
Description: New primary malignancies have been reported more frequently in patients treated with Xgeva® (denosumab 120mg once monthly) compared to zoledronic acid (4mg once monthly), according to…
